Show simple item record

dc.contributor.authorHarrington, KJ
dc.contributor.authorCohen, EEW
dc.contributor.authorSoulières, D
dc.contributor.authorDinis, J
dc.contributor.authorLicitra, L
dc.contributor.authorAhn, M-J
dc.contributor.authorSoria, A
dc.contributor.authorMachiels, J-P
dc.contributor.authorMach, N
dc.contributor.authorMehra, R
dc.contributor.authorBurtness, B
dc.contributor.authorSwaby, RF
dc.contributor.authorLin, J
dc.contributor.authorGe, J
dc.contributor.authorLerman, N
dc.contributor.authorTourneau, CL
dc.coverage.spatialEngland
dc.date.accessioned2024-01-30T10:37:22Z
dc.date.available2024-01-30T10:37:22Z
dc.date.issued2023-12-01
dc.identifierARTN 106587
dc.identifierS1368-8375(23)00283-X
dc.identifier.citationOral Oncology, 2023, 147 pp. 106587 -en_US
dc.identifier.issn1368-8375
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6134
dc.identifier.eissn1879-0593
dc.identifier.eissn1879-0593
dc.identifier.doi10.1016/j.oraloncology.2023.106587
dc.identifier.doi10.1016/j.oraloncology.2023.106587
dc.description.abstractBACKGROUND: In the phase 3 KEYNOTE-040 study, pembrolizumab prolonged OS versus chemotherapy in previously treated recurrent or metastatic (R/M) HNSCC. We present a post hoc subgroup analysis by disease recurrence pattern: recurrent-only, recurrent and metastatic (recurrent-metastatic), and metastatic-only HNSCC. MATERIALS AND METHODS: Patients had HNSCC that progressed during or after platinum-containing treatment for R/M disease or had recurrence or progression within 3-6 months of previous platinum-containing definitive therapy for locally advanced disease. Patients were randomly assigned (1:1) to pembrolizumab 200 mg Q3W or investigator's choice of standards of care (SOC): methotrexate, docetaxel, or cetuximab. Outcomes included OS, PFS, ORR, and DOR. The data cutoff was May 15, 2017. RESULTS: There were 125 patients (pembrolizumab, 53; SOC, 72) in the recurrent-only subgroup, 204 in the recurrent-metastatic subgroup (pembrolizumab, 108; SOC, 96), and 166 in the metastatic-only subgroup (pembrolizumab, 86; SOC, 80). The hazard ratio (95% CI) for death for pembrolizumab versus SOC was 0.83 (0.55-1.25) in the recurrent-only, 0.78 (0.58-1.06) in the recurrent-metastatic, and 0.74 (0.52-1.05) in the metastatic-only subgroups. PFS was similar between treatment arms in all subgroups. ORR was 22.6% for pembrolizumab versus 16.7% for SOC in the recurrent-only, 10.2% versus 6.3% in the recurrent-metastatic, and 15.1% versus 8.8% in the metastatic-only subgroups. DOR was numerically longer with pembrolizumab in all subgroups. CONCLUSION: Pembrolizumab provided numerically longer OS and durable responses in all subgroups compared with SOC, suggesting that patients with previously treated R/M HNSCC benefit from pembrolizumab regardless of recurrence pattern.
dc.formatPrint-Electronic
dc.format.extent106587 -
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIERen_US
dc.relation.ispartofOral Oncology
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectHead and neck squamous cell carcinoma
dc.subjectMetastatic
dc.subjectPembrolizumab
dc.subjectRecurrent
dc.subjectHumans
dc.subjectSquamous Cell Carcinoma of Head and Neck
dc.subjectCetuximab
dc.subjectDocetaxel
dc.subjectMethotrexate
dc.subjectPlatinum
dc.subjectNeoplasm Recurrence, Local
dc.subjectHead and Neck Neoplasms
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.titlePembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.en_US
dc.typeJournal Article
dcterms.dateAccepted2023-10-06
dc.date.updated2024-01-30T10:35:58Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.oraloncology.2023.106587en_US
rioxxterms.licenseref.startdate2023-12-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37925894
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-groupICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-groupICR/ImmNet
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.oraloncology.2023.106587
pubs.volume147
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevin
icr.provenanceDeposited by Mr Arek Surman on 2024-01-30. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S136883752300283X-main.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/